Compare AbCellera Biologics Inc (ABCL) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Tencent Music Entertainment Group - ADR — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Tencent Music Entertainment Group - ADR trades at $8.8 (market cap $14.27B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 6.1× AbCellera Biologics Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 2.78% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TME | |
|---|---|---|
Market Cap | $2.35B | $14.27B |
Sector | Health | Media |
52-Week High | $8.12 | $26.36 |
52-Week Low | $2.78 | $8.16 |
Enterprise Value | $1.99B | $11.05B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
TME trades at $8.62, showing slight daily weakness. The stock presents a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported strong revenue growth to $32.90B in 2025 with a robust net income margin of 26.48%, though recent quarterly earnings have missed expectations. Analyst sentiment is divided with a consensus price target of $14.00, representing significant upside potential from current levels.
The investment case for TME hinges on its solid profitability and reasonable valuation multiples, but faces headwinds from competitive pressures and recent earnings misses. Key risks include intensifying competition in China's music streaming market and potential regulatory scrutiny. The consensus view suggests moderate bullishness with the stock trading below analyst targets, though execution on growth initiatives remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
